Cytek Biosciences, INC Form 4 insider transactions

Philippe Busque, SVP at Cytek Biosciences, reports the acquisition of stock options and restricted stock units.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, receives stock options and restricted stock units as part of her compensation.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding.

Cytek Biosciences' CEO, Wenbin Jiang, reports the vesting of restricted stock units and subsequent tax withholding.

Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported the acquisition of shares through restricted stock unit vesting and subsequent tax withholding.

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported the vesting of restricted stock units and the subsequent withholding of shares to cover tax obligations on November 18, 2024.

Cytek Biosciences CEO Wenbin Jiang acquired shares through the vesting of Restricted Stock Units (RSUs) and subsequently sold some shares to cover tax obligations.

Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reported the acquisition of shares through vesting of restricted stock units and the subsequent withholding of shares for tax obligations.

Cytek Biosciences' Chief Technology Officer, Ming Yan, reported the acquisition of shares through the vesting of restricted stock units and the subsequent withholding of shares for tax obligations on November 18, 2024.

Director Michael Holder of Cytek Biosciences reported the vesting of restricted stock units and subsequent disposal of shares on November 18, 2024.

Cytek Biosciences' CEO, Wenbin Jiang, reported the disposition of 200,000 shares of common stock as a gift on September 14, 2024, while still holding a substantial number of shares.

Director Michael Holder reports the vesting of restricted stock units into Cytek Biosciences common stock.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units related to vesting and tax obligations.

Wenbin Jiang, CEO of Cytek Biosciences, reports transactions involving restricted stock units and common stock, resulting in adjustments to his beneficial ownership.

Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding, resulting in adjustments to beneficial ownership of common stock.

Paul Christopher Williams, COO of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units related to vesting events.

Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reports transactions involving common stock and restricted stock units.

Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported the vesting and subsequent sale of shares to cover tax obligations related to restricted stock units.

Director Michael Holder acquired stock options and restricted stock units in Cytek Biosciences, according to a recent SEC filing.

Director Jack Ball reports acquisition of restricted stock units and stock options in Cytek Biosciences.

Director Deborah Neff reports acquisition of restricted stock units and stock options in Cytek Biosciences.

Director Imper Vera reports acquisition of 15,706 Restricted Stock Units and 23,076 Stock Options in Cytek Biosciences.

Director Don M. Hardison acquired stock options and restricted stock units in Cytek Biosciences, Inc. on June 5, 2024.

Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations on May 20, 2024.

Yan Ming, Chief Technology Officer of Cytek Biosciences, reported the vesting of restricted stock units and subsequent tax withholding, resulting in changes to their beneficial ownership of common stock.

Paul Christopher Williams, COO of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding, resulting in changes to his beneficial ownership of company stock.

Wenbin Jiang, CEO of Cytek Biosciences, reports the vesting and subsequent tax withholding of restricted stock units.

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports transactions involving restricted stock units and common stock, resulting in adjustments to her beneficial ownership.

Philippe Busque, SVP at Cytek Biosciences, reports the vesting and disposal of restricted stock units to cover tax obligations.